Amarin (AMRN) Enters $100M Non-Equity Financing Agreement; Hiring for Vascepa Sales Launch
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Amarin (AMRN) in Focus as Traders Await NCE Decision on Vascepa
December 14, 2012 1:07 PM ESTAmarin (Nasdaq: AMRN) shares are higher on the session as traders anticipate an NCE decision on Vascepa sometime today, though nothing is in stone.
Shares are 24 percent lower from the close on December 6th, with Amarin... More
JPMorgan Doesn't Rule Out Amarin (AMRN) Exploring Sale/Partnership into ANCHOR sNDA, NCE
December 11, 2012 7:58 AM ESTJPMorgan is out with comments on Amarin Corp. (Nasdaq: AMRN) following the company's sales force and financing update for Vascepa last week.
The firm said investors should hang on to the stock moving forward, citing favorable risk-to-reward on the decision. JPMorgan noted that, given the NCE status of Vascepa and that the drug as FDA approval, it is no surprise that the pharma is ready to launch under the MARINE indication. Additionally, ANCHOR is expected to... More
MKM Cuts PT on Amarin (AMRN) to $12; Sees 5% Chance of Partnering on Vascepa Now
December 7, 2012 10:54 AM ESTMKM Partners is keeping its Buy call on Amarin (Nasdaq: AMRN), but cutting its price target by $3 to $12 following Thursday's announcement of new financing and plans to hire more sales staff.
The firm notes that Amarin's moves indicate a "go-it-alone" strategy... More
Lazard Capital Cuts PT on Amarin (AMRN) to $16
December 7, 2012 10:39 AM ESTLazard Capital lowers its price target on Amarin Corporation (NASDAQ: AMRN) from $26 to $16 but maintains its Buy rating after go-it-alone news.
For an analyst ratings summary and ratings history on Amarin Corporation click... More
Canaccord Trims PT on Amarin (AMRN); Sees Increased Commercial Risk, Still Positive on NCE
December 7, 2012 8:43 AM ESTCanaccord Genuity is trimming its price target on Amarin (Nasdaq: AMRN) from $26 down to $19 following news that Amarin is hiring a Vascepa sales force and entering $100 million of new financing, as announced late Thursday. The firm maintains a Buy rating on the stock.
... More
Jefferies Maintains Bullish Stance on Amarin (AMRN) Despite Self Commercialization News
December 7, 2012 8:00 AM ESTJefferies reiterated their Buy and $28 price target on Amarin Corporation (NASDAQ: AMRN) following the company's move to self-commercialize Vascepa.
The firm comments, "AMRN announced a decision to hire a salesforce to launch Vascepa in 1Q13 with a $100m non-dilutive debt... More
Amarin (AMRN) Down 16% after No Sale
December 6, 2012 4:06 PM ESTAmarin Corp Plc (NASDAQ: AMRN) is down a quick 16%, but off the lows, after announcing a $100 million non-equity financing and hiring Vascepa sales force. Investors are disappointed that there was no sale.... More
